The adult transplant programme at Singapore General Hospital (SGH) was established in 1985 and more than 820 transplants have been performed to date. An average of about 60 adult transplants (autologous and allogeneic) are performed each year. Transplants offered at SGH run the range from autologous to mismatched cord and unrelated transplants. Special interests of the transplant programme include non-myeloablative transplants in aplastic anaemia, cell therapy protocols including cytokine-induced killer cells, patterns of GVHD, cord blood transplantation for autoimmune diseases and graft engineering. A cGMP (good manufacturing practice) cell therapy laboratory was recently established to facilitate bench-to-bedside translational cell therapy trials. A BMT consortium has been formed among the various paediatric and adult transplant centres for harmonization of protocols and research activities.
There are altogether two adult and two paediatric centres offering both autologous as well as allogeneic transplants and one smaller centre recently established in a private hospital. All the centres perform the full range of transplants: sibling, unrelated, cord and mismatched. Singapore is a small country with excellent infrastructure and good access to affordable health care. Its health indices mirror that of any developed country. The population of the country is in excess of four million with a target of six million in the next decade. This is a multiracial society with the majority (70%) consisting of ethnic Chinese, 18%
Malays, 9% Tamils and a growing, significant expatriate population working and living in the country.
In addition to the local population, a significant number of patients from neighbouring countries also come to Singapore to seek specialist health care. One of these areas is SCT, which requires an intensive multidisciplinary medical, nursing and environmental support that may be absent in the region. The emphasis on placing itself as a medical hub has also seen an influx of patients farther from the usual catchment region to include the Middle East and the West.
The adult transplant programme at SGH was established in 1985 and more than 820 transplants have been performed to date. An average of about 60 adult transplants (autologous and allogeneic) are performed each year with smaller numbers in the other hospitals. This is currently staffed by four consultants, one associate consultant and a team of trainees and medical officers. The infrastructure specific to the transplant programme includes high efficiency particulate air (HEPA)-filtered rooms, specially trained nursing staff, a transplant coordinator, dedicated pharmacists, a stem cell processing laboratory, a molecular lab including chimerism monitoring and a day centre for transplant follow-up.
Another component integral to the success of the transplant programme is the input provided by the infectious disease physicians. A weekly joint ward round is conducted with a review of clinical progress and radiographic investigations. The majority of the population is CMV-positive and reactivation is common, especially in the presence of any T-cell depletion including Campath and antithymocyte globulin. Usual (aspergillosis) and unusual (conidiobolomycosis) fungal infections are also seen with active participation in antifungal clinical trials.
1,2 Regular transplant meetings are held with the aim of reaching consensus on patient treatment plans among all the consultants and medical staff.
The transplant programme is supported by a tissuetyping laboratory that is currently undergoing ASHI accreditation and an American Association of Blood Banks (AABB)-accredited blood banking establishment.
Transplants offered at SGH run the range from autologous to mismatched cord and unrelated transplants. Double cord transplants are also practised and a national cord blood bank facility is available. The myeloablative regimens follow the standard BU/CY for myeloid malignancies and CY/TBI for lymphoid malignancies, whereas the backbone of the non-myeloablative protocols has been fludarabine and low-dose TBI. The range of diseases transplanted is similar, the bulk of which are haematological malignancies. An autologous autoimmune programme is present, including transplantation for multiple sclerosis. Although other non-malignant haematological malignancies are also transplanted (see aplastic anaemia below), a very successful prevention programme for thalassaemias has markedly reduced numbers requiring transplants.
The special interests of the transplant programme are the following:
Aplastic anaemia
The incidence of aplastic anaemia appears to be higher in this region, as previously documented in other papers. A wider age group is also seen, including that of the older subset thought previously to be less amenable to transplantation. Initial good results with a non-myeloablative regimen (fludarabine/TBI) as the second-line therapy for failed antithymocyte globulin has seen the introduction of transplantation as initial therapy for aplastic anaemia even in the older age group. The data for the first eight patients have been reported recently and demonstrate encouraging disease-free survival data (Tables 1 and 2) . 3 Although engraftment is not an issue, invasive fungal infections remain the sole cause of death and severe GVHD (grade Table 1 Baseline characteristics, grafts and GVHD prophylaxis of eight patients with AA III-IV) in 25% of patients until some revision to the GVHD prophylaxis protocol is instituted (Tables 1 and 2 ).
GVHD
The incidence of GVHD seen is roughly similar to that reported worldwide, although the patterns of manifestations appear different. Liver and gut GVHD are the most common sites affected, whereas skin GVHD is relatively less common. If present, most cases of skin GVHD have been self-limiting, grade I-II and some have been difficult to distinguish from a possible reaction to concomitant medication (clinical with no biopsy correlate). The skin cases have also tended to manifest as limited chronic GVHD with very little sclerodermatous type seen. As for the liver, in contrast to the classical rises seen in alkaline phosphatases and bilirubin as reported in the literature, the Asian patients often present with a hepatitic picture.
These interesting observations are currently being prepared as a manuscript for submission.
Initial post-grafting immune suppression in the non-myeloablative setting has been with CYA and mycophenolate. Owing to high rates of severe GVHD, a triple regimen incorporating MTX has been introduced with a significant drop in incidence of GVHD and an increase in overall survival and non-relapse mortality (Table 3 and Figure 1 ). 4 Extracorporeal photopheresis has also been introduced recently as an additional modality in the treatment of GVHD.
Graft engineering CD34 selection is practised and there is an ongoing trial with CD8-depleted donor lymphocyte infusions. A selective depletion trial using CD69 for the prevention of GVHD, while preserving antiviral and antileukaemia activity, is currently being looked at for clinical scale-up. 5 
Cell therapy protocols
There is an active emphasis on developing novel cellular immunotherapy protocols to improve survival rates in transplant. There is an ongoing clinical trial that commenced in 2006 and is currently accruing patients using ex vivo expanded autologous and allogeneic cytokine-induced killer cells as an adjuvant post transplant or in relapse. 6, 7 The cells are expanded in a cGMP (good manufacturing practice) Cell Therapy Laboratory located at the Centre for Transfusion Medicine, Health Sciences Authority. There are plans to increase the size of this facility due to the increasing number of cell therapy trials planned.
Other cellular products currently investigated in the cGMP cell therapy facility include mesenchymal stem cells and natural killer cells. 8 
Haplo-identical transplant programme
In an effort to harmonize protocols and research activities, a BMT consortium was set up in 2006 with participation from all the transplant centres except the private facility. Workgroups within this consortium have been working on validating CD34 enumeration, immune reconstitution monitoring and developing novel conditioning GVHD and cell therapy protocols.
The advent of mismatched cord blood transplants has also allowed for the eligibility of allogeneic transplants for a wider group of patients. Small family size is a common characteristic in the Singapore demographic and this means a lesser chance of finding a suitable sibling match. Unrelated searches yielding potential adult matches have also been less successful than in the West owing to the preponderance of Caucasian donors. The enlargement of the Taiwanese and introduction of the Chinese registries have somewhat redressed that imbalance a little, whereas a smaller Singapore-based donor registry continues to expand as well. The provision of grant funding for unrelated searches has also been a significant step forward.
Research activities in transplantation have been focused in particular on cord blood transplants, cellular immunotherapy protocols, immune reconstitution and new conditioning regimens for transplants including GVHD prophylaxis. There is a strong research focus on stem cells including embryonic stem cells and potential clinical use. A dedicated national research facility, A*STAR, offers potential for clinical translational trials. Grant funding is provided to the BM consortium for its research activities. Clinical trials including the recent pivotal antifungal trial are also conducted within the proper research framework that exists in Singapore (Institutional Review Board, patient consent and so on). 2 The emergence of stem cell treatment for non-haematological diseases including neurological and cardiac applications will ensure that the healthy transplant programme continues to grow in Singapore.
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